Last reviewed · How we verify
NurOwn® (MSC-NTF cells)
NurOwn delivers mesenchymal stem cells engineered to secrete neurotrophic factors that support motor neuron survival and function in amyotrophic lateral sclerosis (ALS).
NurOwn delivers mesenchymal stem cells engineered to secrete neurotrophic factors that support motor neuron survival and function in amyotrophic lateral sclerosis (ALS). Used for Amyotrophic lateral sclerosis (ALS).
At a glance
| Generic name | NurOwn® (MSC-NTF cells) |
|---|---|
| Also known as | NurOwn |
| Sponsor | Brainstorm-Cell Therapeutics |
| Drug class | Cell therapy |
| Target | Neurotrophic factors (NGF, BDNF, GDNF) |
| Modality | Biologic |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
NurOwn (MSC-NTF cells) consists of autologous bone marrow-derived mesenchymal stem cells that have been differentiated ex vivo to produce and secrete neurotrophic factors, including nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and glial-derived neurotrophic factor (GDNF). These factors are intended to slow motor neuron degeneration and preserve motor function in ALS patients. The cells are injected intrathecally into the cerebrospinal fluid to deliver these neuroprotective factors directly to affected motor neurons.
Approved indications
- Amyotrophic lateral sclerosis (ALS)
Common side effects
- Back pain
- Headache
- Procedural pain at injection site
- Transient lower limb weakness
Key clinical trials
- Expanded Access Protocol: Repeated Administration of Nurown® (Autologous MSC-NTF Cells) for the Treatment of ALS
- Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients (PHASE3)
- Safety and Efficacy of Repeated Administration of NurOwn (MSC-NTF Cells) in Participants With Progressive MS (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NurOwn® (MSC-NTF cells) CI brief — competitive landscape report
- NurOwn® (MSC-NTF cells) updates RSS · CI watch RSS
- Brainstorm-Cell Therapeutics portfolio CI